Introduction
============

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in Asian countries, and surgical resection may be the only treatment means ([@b1-ol-0-0-9374]--[@b3-ol-0-0-9374]). However, only \>20% patients are eligible for surgical treatment ([@b4-ol-0-0-9374]). Even for patients who are able to receive surgical treatment, HCC will eventually relapse in approximately 30--60% of them ([@b5-ol-0-0-9374]). Non-surgical treatment means include transcatheter arterial chemoembolization (TACE), percutaneous acetic acid and ethanol injection therapy and precise radiation therapy (RT). Several authoritative agencies have reported that patients with unresectable HCC can benefit a lot from receiving partial liver RT ([@b6-ol-0-0-9374],[@b7-ol-0-0-9374]), especially those with portal venous thrombosis or invasive liver tumor ([@b8-ol-0-0-9374],[@b9-ol-0-0-9374]). With the development of three-dimensional conformal intensity-modulated RT technique, namely the precise RT, partial liver RT has become safer. Although the effect of RT at the radiation site is significant, HCC frequently relapses in other intrahepatic sites or develops into extrahepatic metastasis in patients treated with RT alone ([@b10-ol-0-0-9374]). Human p53 gene, located on the short arm of chromosome 17, encodes a 53 kDa nuclear phosphoprotein, which is an important negative regulator of cell growth ([@b11-ol-0-0-9374],[@b12-ol-0-0-9374]). The wild-type p53, as a product of tumor suppressor gene protein, regulates the cell cycle. Besides, wild-type p53 has a shorter half-life (20 min), so it is difficult to detect p53 protein in normal tissues. However, p53 gene mutation is often detected in a variety of human tumor tissues, and the half-life of products after p53 gene mutation is prolonged and the function of regulating cell cycle is lost, thus making cell growth out of control ([@b13-ol-0-0-9374]). However, the correlations of TACE and RT with serum p53 level and therapeutic effect on HCC have not been clearly reported.

In this experiment, HCC patients were treated with TACE combined with RT and TACE alone, so as to investigate whether the two methods can increase the serum p53 level in patients and comprehensively evaluate the clinical effects of the two treatment methods.

Materials and methods
=====================

### Clinical data

A total of 80 patients with unresectable HCC treated in the Emergency Treatment of the First People\'s Hospital of Qinhuangdao (Qinhuangdao, China) from March 2009 to March 2015 were selected. Inclusion criteria were determined by surgeons based on the currently-accepted surgical criteria. Seventy-two cases were histologically confirmed as HCC, while the remaining 8 cases were not confirmed histologically due to the refusal of biopsy, but the imaging examination and biochemical test results were consistent with HCC. None of patients enrolled received any anticancer therapy before operation. Patients were aged 36--78 years old with an average age of 58.4±7.9 years old, and general clinicopathological data had no statistically significant differences. All patients signed the informed consent, and this clinical test was approved by the Ethics Committee of the First People\'s Hospital of Qinhuangdao.

### Grouping and treatment methods

In this study, 80 HCC patients were randomly divided into TACE group (n=40) and TACE + RT group (n=40). TACE treatment: The catheter was inserted into the hepatic artery via femoral artery using Seldinger technique, followed by hepatic arteriography. After the correct positioning of catheter, 30--50 mg doxorubicin and 20 mg hydroxycamptothecine were used as chemotherapy drugs. Thirty milliliters ultra-fluid lipiodol embolic agent and gelatin sponge particles were used for embolization. The treatment was performed for 3 times (1 time/month). TACE + RT: Patients underwent RT after TACE treatment for 3 times. After oral administration of contrast agent, the radiation area was accurately determined under the guidance of spiral computed tomography (CT). Be careful to avoid the entire liver from being in the radiation area. Gross target volume (GTV) was drawn under the assistance of computer. The outward expansion for 1 cm based on GTV indicated the clinical target volume (CTV). According to the location and size of tumor, the outward expansion for 1.5--2 cm based on CTV indicated the planning target volume (PTV). The average tumor dose was 44 Gy. During treatment, the liver function of patients was examined once a week.

### Detection of p53 and biochemical indexes

The blood was drawn from all patients before and after treatment, let stand at room temperature for 1 h, and stratified. The upper-layer serum was taken to detect the serum p53 protein level using the enzyme-linked immunosorbent assay (ELISA) kit (cat. no. ab171571; Abcam, Cambridge, NY, USA) according to instructions. The levels of biochemical indexes of liver function \[α-fetoprotein (AFP), alanine aminotransferase (ALT) and γ-glutamyl transferase (GGT)\] were determined by the Laboratory Department of our hospital.

### Therapeutic effect evaluation and follow-up

According to the modified response evaluation criteria in solid tumors (mRECIST) ([@b14-ol-0-0-9374]), tumor response was evaluated at 3 months after treatment based on the observation of changes in tumor size via dynamic CT scan: Complete remission (CR), complete disappearance of tumors; partial remission (PR), decrease of tumor size to 50% of the initial volume; stable disease (SD), decrease of tumor size to \<30% of the initial volume or no change and progressive disease (PD). The response rate of CR, PR, SD or PD was calculated. The overall response rate (RR) = CR + PR, and the disease control rate (DCR) = CR + PR + SD. Patients were followed up via outpatient or telephone after treatment for 18 months. In this experiment, 6 cases were lost to follow-up, and the remaining 74 cases were in the study cohort.

### Statistical methods

GraphPad Prism statistical software (version 5.01; GraphPad Software, Santiago, Chile) was used for analysis. Chi-square test was used for the correlations of general clinicopathologic data between the two groups of patients. The progression-free survival (PFS) and overall survival (OS) curves of the two groups of patients were drawn using Kaplan-Meier method, and the survival differences between the two groups were compared by log-rank test. Measurement data were presented as (mean ± SD), and independent-samples t-test was used to compare the difference in p53 expression between the two groups. P\<0.05 suggested that the difference was statistically significant.

Results
=======

### Comparisons of general clinicopathologic data between the two groups of patients

There were no statistically significant differences in age, sex, serum albumin, liver function classification, cirrhosis, tumor size, tumor capsule, number of tumors, Edmondson-Steiner grading and vascular invasion in patients between TACE + RT group and TACE group (P\>0.05) ([Table I](#tI-ol-0-0-9374){ref-type="table"}), and follow-up experiments could be performed.

### p53 expression level

There was no statistically significant difference in the p53 protein level between the two groups of patients before treatment (P\>0.05). After treatment, the levels of p53 protein in both groups were decreased compared with those before treatment (P\<0.05), and it was lower in TACE + RT group than that in TACE group (P\<0.05) ([Fig. 1](#f1-ol-0-0-9374){ref-type="fig"}).

### Changes in relevant biochemical indexes in both groups of patients before and after treatment

AFP, ALT and GGT levels had no statistically significant differences in both groups of patients before treatment (P\<0.05). After treatment, AFP and GGT levels in both groups of patients were decreased compared with those before treatment, but ALT levels were increased compared with those before treatment (P\<0.05). TACE + RT group had a better curative effect than TACE group (P\<0.05) ([Table II](#tII-ol-0-0-9374){ref-type="table"}).

### Adverse reactions in both groups of patients

After patients received TACE and/or RT, common adverse reactions include infection, hepatic failure, leucopenia, diarrhea, nausea, hematemesis, and elevated blood pressure. In this experiment ([Table III](#tIII-ol-0-0-9374){ref-type="table"}), there was 1 case of infection, 3 cases of hepatic failure, 2 cases of leucopenia, 6 cases of diarrhea, 1 case of hematemesis, 10 cases of headache and vertigo, and 3 cases of elevated blood pressure in TACE group, and the incidence rate of adverse reactions was 65%. In TACE + RT group, there was 1 case of hepatic failure, 1 case of leucopenia, 4 cases of diarrhea, 8 cases of headache and vertigo and 1 case of elevated blood pressure, and the incidence rate of adverse reactions was 37.5%, which was significantly lower than that in TACE group (P\<0.05).

### Comparisons of short-term treatment effects between both groups of patients

SD and DCR of patients in TACE + RT group were obviously higher than those in TACE group, but PD was lower than that in TACE group (P\<0.05) ([Table IV](#tIV-ol-0-0-9374){ref-type="table"}).

### Comparison of survival time

In TACE group, the 2-year survival rate of patients was 22.7%, the median PFS was 6.45 months, and the median OS was 9 months. In TACE + RT group, the 2-year survival rate was 37.4%, the median PFS was 10.54 months, and the median OS was 13.4 months. The results showed that patients in TACE + RT group had longer survival time than those in TACE group (P\<0.05) ([Table V](#tV-ol-0-0-9374){ref-type="table"} and [Fig. 2](#f2-ol-0-0-9374){ref-type="fig"}).

Discussion
==========

TACE is one of the main treatment methods for HCC, especially unresectable and advanced HCC. TACE exerts an anticancer effect by selectively blocking the arterial blood supply of HCC. TACE can be used for multiple intrahepatic tumors. However, due to complex blood supply, it is less effective in the control of larger tumors ([@b15-ol-0-0-9374]). The blood supply of small tumors is usually in the hepatic artery only, and the blood supply in extrahepatic artery is increased in large tumors. RT can be used as a complement to TACE for large tumors ([@b16-ol-0-0-9374]). Due to the limitations of radiotherapy techniques in the past, HCC was mistakenly considered as an RT-insensitive tumor ([@b17-ol-0-0-9374]). With the development of precision medicine and modern radiotherapy techniques (such as three-dimensional conformal radiotherapy and intensity-modulated radiotherapy) at present, tumors can be treated at higher doses, and normal tissues around the tumor can be better protected. Now, RT is a safe and effective treatment means for primary HCC, and its role is gradually being taken seriously ([@b18-ol-0-0-9374]).

Matsuura *et al* reported 22 cases of simple RT or TACE + ethanol injection therapy ([@b19-ol-0-0-9374]). In the study of Seong *et al*, 30 cases received TACE treatment at 7--10 days after local RT ([@b20-ol-0-0-9374]). Im *et al* treated HCC patients with RT twice a day, as well as hepatic arterial infusion of fluorodeoxyuridine ([@b9-ol-0-0-9374]). Jung and Shin treated 3--8 cm HCC with TACE, ethanol injection and RT ([@b21-ol-0-0-9374]). These experiments show that TACE combined with RT has a better curative effect than TACE or RT alone.

Functional inactivation of p53 is related to many different mechanisms, including: i) p53 forms stable non-functional complexes with viral proteins, ii) p53 binds to intracellular proteins, such as heat shock protein 70, leading to loss of normal function of p53, and iii) p53 mutation: p53 mutations are found in 60--65% human tumors, and this is also a major cause of p53 functional inactivation ([@b22-ol-0-0-9374]). Types of p53 gene mutations include point mutation, deletion mutation, frameshift mutation and gene rearrangement. Mutation sites are more concentrated in the first 5--8 exons. Abnormal protein is produced and accumulates in cancer cells. Its half-life is also increased from 15--20 min to a few hours. At present, it has been reported that the injection of p53 gene with overexpression of p53 virus can replace the mutated p53 site, thus promoting p53 to play a role in inhibiting tumor growth ([@b23-ol-0-0-9374]).

According to our data, TACE combined with RT offers greater benefit to tumor patients than TACE alone. PFS and OS of patients in TACE + RT group were longer than those in TACE group, and the 2-year survival rate in TACE + RT group was up to 37.4%, which was higher than that in TACE group. Importantly, p53 in serum of patients in TACE + RT group was significantly decreased, compared with that in TACE group. It is reported in the literature that DNA damage in tumor cells is induced after gamma-ray irradiation, thereby increasing the level of p53 protein phosphorylation ([@b24-ol-0-0-9374]). In addition, studies have shown that the wild-type p53 expression is increased after RT for more than 96 h ([@b25-ol-0-0-9374]), which may be an important reason for the improved prognosis of patients. The specific mechanism remains to be further proved via experiments. In this experiment, in addition to higher ALT and GGT levels after treatment, AFP in patients in TACE group also remained at a relatively high level. AFP is a factor of poor prognosis of HCC patients, which may be one of the reasons for poorer prognosis of patients in TACE group than that in TACE + RT group.

In conclusion, this study showed that the treatment of patients who cannot receive surgical treatment with simple TACE leads to poor survival, serious disease and short survival time. However, TACE combined with RT can significantly increase the survival time and improve the prognosis of patients.
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###### 

Comparisons of general clinicopathologic data between the two groups of patients.

                                  Training cohort (80 cases)             
  ------------------------------- ---------------------------- ---- ---- -------
  Age (years)                                                            
    ≤60                           46                           19   17   0.643
    \>60                          34                           21   13   
  Sex                                                                    
    Male                          47                           18   29   0.529
    Female                        33                           12   11   
  Serum albumin                                                          
    ≤35 g/l                       44                           20   22   0.392
    \>35 g/l                      36                           20   16   
  Liver function classification                                          
    Child-Pugh A                  37                           21   16   0.301
    Child-Pugh B                  43                           19   24   
  Cirrhosis                                                              
    No                            41                           16   25   0.105
    Yes                           39                           24   15   
  Tumor size (cm)                                                        
    ≤5                            49                           25   24   0.736
    \>5                           31                           15   16   
  Tumor capsule                                                          
    No                            42                           27   25   0.250
    Yes                           38                           13   25   
  No. of tumors (cm)                                                     
    Single                        49                           27   22   0.738
    Multiple                      31                           13   18   
  Edmondson-Steiner grading                                              
    I--II                         50                           30   20   0.087
    III--IV                       30                           10   20   
  Vascular invasion                                                      
    No                            37                           25   12   0.092
    Yes                           43                           15   28   

TACE, transcatheter arterial chemoembolization; RT, radiation therapy.

###### 

Changes in AFP, ALT and GGT levels in both groups of patients before and after treatment (mean ± SD).

              AFP (µg/l)     ALT (U/l)                                                                                               GGT (U/l)                                                                                                                            
  ----------- -------------- ------------------------------------------------------------------------------------------------------- ------------- ------------------------------------------------------------------------------------------------------- -------------- -------------------------------------------------------------------------------------------------------
  TACE        513.76±78.22   367.36±98.90^[b](#tfn4-ol-0-0-9374){ref-type="table-fn"},[d](#tfn6-ol-0-0-9374){ref-type="table-fn"}^   51.63±10.73   124.23±85.26^[b](#tfn4-ol-0-0-9374){ref-type="table-fn"},[c](#tfn5-ol-0-0-9374){ref-type="table-fn"}^   410.56±76.30   243.51±83.23^[b](#tfn4-ol-0-0-9374){ref-type="table-fn"},[c](#tfn5-ol-0-0-9374){ref-type="table-fn"}^
  TACE + RT   553.81±92.73   201.82±84.77^[b](#tfn4-ol-0-0-9374){ref-type="table-fn"}^                                               48.93±13.62   176.17±79.43^[b](#tfn4-ol-0-0-9374){ref-type="table-fn"}^                                               394.73±92.84   158.83±93.47^[a](#tfn3-ol-0-0-9374){ref-type="table-fn"}^

Compared with that before treatment:

P\<0.05

P\<0.01. Compared with that in TACE group:

P\<0.05

P\<0.01. AFP, α-fetoprotein; ALT, alanine aminotransferase; GGT, γ-glutamyl transferase.

###### 

Adverse reactions in both groups of patients.

  Groups      No.   Infection   Hepatic failure   Leucopenia   Diarrhea   Hematemesis   Headache and vertigo   Elevated blood pressure   Incidence rate of adverse reactions (%)
  ----------- ----- ----------- ----------------- ------------ ---------- ------------- ---------------------- ------------------------- -----------------------------------------
  TACE        40    1           3                 2            6          1             10                     3                         65 (26/40)
  TACE + RT   40    0           1                 1            4          0               8                    1                         37.5 (15/40)
  c^2^                                                                                                                                   1.252
  P-value                                                                                                                                0.047

TACE, transcatheter arterial chemoembolization; RT, radiation therapy.

###### 

Response rates to different treatment methods in both groups of HCC patients.

  Items   TACE (n=40) n (%)   TACE + RT (n=40) n (%)   P-value
  ------- ------------------- ------------------------ ---------
  CR      0 (0)               0 (0)                    --
  PR      4 (10)              6 (15)                   --
  SD      16 (40)             23 (57.5)                0.047
  PD      26 (65)             17 (42.5)                0.041
  RR      4 (10)              6 (15)                   --
  DCR     20 (50)             29 (72.5)                0.032

HCC, hepatocellular carcinoma; TACE, transcatheter arterial chemoembolization; RT, radiation therapy; CR, complete remission; PR, partial remission; SD, stable disease; PD, progressive disease; RR, response rate; DCR, disease control rate.

###### 

Comparison of survival time between both groups of patients.

  Groups      2-year survival rate (%)   Median PFS (months)   Median OS (months)
  ----------- -------------------------- --------------------- --------------------
  TACE        22.7                       6.45                  9
  TACE + RT   37.4                       10.54                 13.4
  c^2^        3.321                      5.341                 4.825
  P-value     0.043                      0.0261                0.0350

TACE, transcatheter arterial chemoembolization; RT, radiation therapy; PFS, progression-free survival; OS, overall survival.
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